Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer.

Journal of clinical pathology - 1 Feb 2021

Ng Isaac Ks, Kumarakulasinghe Nesaretnam Barr, Syn Nicholas L, Soo Ross Andrew

Abstract excerpt

AIMS: EGFR tyrosine kinase inhibitors (TKIs) are first-line molecularly targeted therapies in patients with advanced non-small cell lung cancer (NSCLC) who carry sensitising EGFR mutations, due to its superior survival outcomes compared with conventional chemotherapy regimens. In this study, we sought to identify clinical, immune and biochemical variables with prognostic significance in this patient subgroup and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to L-Lactate Dehydrogenase

Share to Nomograms

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Identifiers

PMID: 32576630
DOI: 10.1136/jclinpath-2020-206754

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer.PMID 32576630Read ↗

Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.Semantic proximity Read ↗

Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index).Semantic proximity Read ↗

Prognostic nomograms for hormone receptor-positive breast cancer with lung metastasis: a SEER-based studySemantic proximity Read ↗

Development and Validation of a Survival Prediction Model for Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study.Semantic proximity Read ↗

Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.Semantic proximity Read ↗

Prognostic nomograms for hormone receptor-positive breast cancer with lung metastasis: a SEER-based study with external validationSemantic proximity Read ↗

Development and validation of two prognostic nomograms for predicting survival in patients with non-small cell and small cell lung cancerSemantic proximity Read ↗

Identifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors.Semantic proximity Read ↗

The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.Semantic proximity Read ↗

Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels.Semantic proximity Read ↗

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.